d-Amino acid mutation of PMI as potent dual peptide inhibitors of p53-MDM2/MDMX interactions

Bioorg Med Chem Lett. 2017 Oct 15;27(20):4678-4681. doi: 10.1016/j.bmcl.2017.09.014. Epub 2017 Sep 7.

Abstract

According to the previously reported potent dual l-peptide PMI of p53-MDM2/MDMX interactions, a series of d-amino acid mutational PMI analogues, PMI-1-4, with enhanced proteolytic resistence and in vitro tumor cell inhibitory activities were reported, of which Liposome-PMI-1 showed a stronger inhibitory activity against the U87 cell lines than Nutlin-3. This d-amino acid mutation strategy may give a hand for enhancing the potential of peptide drugs.

Keywords: MDM2/MDMX; P53; PMI; Peptides; Tumor; d-Amino acid.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Sequence
  • Amino Acids / metabolism
  • Binding Sites
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Cell Survival
  • Circular Dichroism
  • Humans
  • Liposomes / chemistry
  • Molecular Dynamics Simulation
  • Peptide Library
  • Peptides / chemistry
  • Peptides / metabolism*
  • Peptides / pharmacology
  • Protein Interaction Domains and Motifs / drug effects
  • Protein Structure, Tertiary
  • Proto-Oncogene Proteins c-mdm2 / antagonists & inhibitors
  • Proto-Oncogene Proteins c-mdm2 / metabolism*
  • Tumor Suppressor Protein p53 / antagonists & inhibitors
  • Tumor Suppressor Protein p53 / metabolism*

Substances

  • Amino Acids
  • Liposomes
  • Peptide Library
  • Peptides
  • Tumor Suppressor Protein p53
  • Proto-Oncogene Proteins c-mdm2